Amphastar Pharmaceuticals Inc. (AMPH) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (49.5% gross margin, 9% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-03, Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $27.03 (-2.49% 1D, market cap $1.18B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, AMPH ranks #61 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMPH carries a Roarable B (72/100 RQD), trailing P/E of 11.7x, gross margin of 49.5%, and ROIC of 9.0%. By comparison, VSTM (Verastem Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.18B) and RAPP (Rapport Therapeutics Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -22.9%, cap $1.20B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).
Per AMPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001297184), Amphastar Pharmaceuticals Inc. generated $719.9M in revenue (-1.7% YoY), $98.1M in net income, and $121.2M in free cash flow against $1.63B in total assets and $619.7M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
20D Institutional Volume Accumulation (±6.8% realized swing band)
Balance-sheet & 10-K footnote risk deducts 9 pts from forensic ceiling
Even with a 72/100 (B) score, AMPH faces multiple-compression risk if 11.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 47.0% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($25.00) or 200D SMA ($22.26) invalidates the momentum regime and cuts Target Base ($28.73) toward Bear Floor ($22.16).
Amphastar Pharmaceuticals Inc. (AMPH) dropped -2.49% to $27.03, trading at 81% of its 52-week range ($16.65 – $29.52). High-quality cash engine (49.5% gross margin, 9% return on capital) with steady institutional support.
Yahoo! Finance Canada report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
StockStory report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of +30.00% and +19.08%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its third quarter of 2026 ended September 30, 2026, after the market closes on Thursday, November 5, 2026, and will
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -1.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AMPH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AMPH. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Amphastar Pharmaceuticals Inc. (AMPH) ranks #61 by composite RQD confidence (72/100, grade B) and #335 by equity capitalization ($1.18B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AMPH
ACTIVE
Amphastar Pharmaceuticals Inc. | B | 72/100 | 11.7x | 49.5% | 9.0% | -2.49% | $1.18B | Benchmark Subject |
| VSTM Verastem Inc. | D- | 36/100 | — | — | -35.0% | -1.64% | $1.18B | /vstm-vs-amph → |
| RAPP Rapport Therapeutics Inc. | E | 30/100 | — | — | -22.9% | +0.32% | $1.20B | /rapp-vs-amph → |
| SNDX Syndax Pharmaceuticals Inc. | E | 17/100 | — | — | -35.0% | -4.03% | $1.22B | /sndx-vs-amph → |
| AVLN Avalyn Pharma Inc. | D | 44/100 | — | — | — | -0.12% | $1.14B | /avln-vs-amph → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amphastar Pharmaceuticals Inc. (AMPH) reported GAAP revenue of $719.9M (-1.7% vs. FY2024 revenue of $732.0M , and +11.7% cumulative change since FY2023) , GAAP net income of $98.1M, operating cash flow of $156.1M, and free cash flow of $121.2M (-29.7% YoY). On the balance sheet, AMPH closed FY2025 with $1.63B in total assets against $619.7M in total debt (Altman Z-Score: 2.47, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $719.9M | $98.1M | $156.1M | $121.2M | $1.63B | $619.7M |
| FY2024 (FY) | 2024-12-31 | $732.0M | $159.5M | $213.4M | $172.3M | $1.58B | $613.5M |
| FY2023 (FY) | 2023-12-31 | $644.4M | $137.5M | $183.5M | $183.5M | — | — |
As of 2026-11-03, Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $27.03 (-2.49% 1D, market cap $1.18B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, AMPH ranks #61 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMPH carries a Roarable B (72/100 RQD), trailing P/E of 11.7x, gross margin of 49.5%, and ROIC of 9.0%. By comparison, VSTM (Verastem Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.18B) and RAPP (Rapport Therapeutics Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -22.9%, cap $1.20B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).
Per AMPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001297184), Amphastar Pharmaceuticals Inc. generated $719.9M in revenue (-1.7% YoY), $98.1M in net income, and $121.2M in free cash flow against $1.63B in total assets and $619.7M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.
AMPH last traded at $27.03 (-2.49% on volume of 497,733 shares), positioning the stock +8.12% above its 50-day simple moving average ($25.00) and +21.43% above its 200-day simple moving average ($22.26). Across its 52-week range of $16.65 to $29.52, AMPH sits at the 80.7% percentile with a 14-day RSI of 63.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.8% ($25.19 to $28.87).
Amphastar Pharmaceuticals Inc. (AMPH) earns a live Roarable RQD composite score of 72/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $27.03 (-2.49% 1D, market capitalization $1.18B).
Amphastar Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations..1B. Per the market data, gross margin is 49.5%, operating margin 19.5%, and net margin 13.6%. — for: specific product lines, customer segments, or the detailed revenue model.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Amphastar Pharmaceuticals Inc. (AMPH) reported $719.9M in annual revenue (up from $732.0M in FY2024, -1.7% YoY) and $98.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($644.4M revenue, $137.5M net income) through FY2025, AMPH scaled operating cash flow to $156.1M and free cash flow to $121.2M, backed by $1.63B in total assets against $619.7M in total debt.
The supply chain is NONE, with no upstream or downstream links and no proprietary signals recorded. A prospective investor should note that the absence of mapped links means no supply-chain ripple analysis is supported by this dataset.
Real-time company headlines, analyst actions, and sector developments for Amphastar Pharmaceuticals Inc. (AMPH) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
StockStory report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Amphastar Pharmaceuticals Inc. (AMPH) market action, institutional positioning, and fundamental catalysts.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Long AMPH at $27.72 targeting $36.59. A 10.58% FCF yield and 10.9x forward P/E sit alongside an insider-conviction pillar score of 17/20, suggesting cash generation is priced cheaply relative to its stated cash flow.. Institutional whale score is 16/20 and the risk/reward vs. the $16.65 52-week low is skewed heavily in favor of bulls.
Both sides have a point here — AMPH's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Fading this rally in AMPH at $27.72. Revenue, net income, and FCF all declined from FY 2024 to FY 2025 while debt rose to $619.7M, and the forensic balance sheet pillar scored lowest at 11/20.. With a beta of 1.0 and the stock sitting at $27.72 (52-wk range $16.65–$29.52), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: